Can aggressive lipid lowering using low-density lipoprotein apheresis prevent restenosis after percutaneous transluminal coronary angioplasty in patients with normocholesterolemia?

Therapeutic Apheresis

Volumn 2, Issue 3, 1998, Pages 210-217

  Yamashita, Kazuhito ^a,b   Tasaki, Hiromi ^a   Tsuda, Yuki ^a   Himeno, Etsuro ^a   Nakashima, Yasuhide ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Iwate Rosai Hospital   (Japan)

Author keywords

Low density lipoprotein apheresis; Percutaneous transluminal coronary angioplasty; Restenosis

Indexed keywords

LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN;

ANGIOCARDIOGRAPHY; APHERESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031685354     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1998.tb00106.x     Document Type: Article

References (12)

1. Levine S, Ewels CI, Rosing DR, Kent KM. Coronary angioplasty: Clinical and angiographic follow-up. Am J Cardiol 1985;55:673-6.
2. Rensing BJ, Hermans WR, Vos J, Tijssen JG, Rutch W, Danchin N, Heyndrick GR, Mast EG, Wijns W, Serruys PW. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation 1993;88:975-85.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac-Farlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
4. Johansson SR, Wiklund O, Karlsson T, Hjalmarson A, Emanuelsson H. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. Eur Heart J 1991;12:1020-8.
5. Cooke T, Sheahan R, Foley D, Reilly M, D'Arcy G, Jauch W, Gibney M, Gearty G, Crean P, Walsh M. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994;89:1593-8.
6. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB III, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-7.
7. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty. J Am Coll Cardiol 1997;30:863-9.
8. Michishita I, Shibazaki Y, Umeda K, Mizuno K, Watanabe S, Genda A. Serum lipoprotein(a) as a restenosis risk factor after percutaneous transluminal coronary angioplasty (abstract). Circulation 1991;84(Suppl (II):484.
9. Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SB III, Lembo NJ, Roubin GS, Sgoutas DS. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-9.
10. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994;90:2267-79.
11. Brawn WV, Levy RI, Fredrickson DS. Studies of proteins in human very-low-density lipoproteins. J Biol Chem 1969;2441:5687-94.
12. Warnick GR, Cheung MC, Albers JJ. Comparison of current methods for high-density lipoproteins. J Biol Chem 1969;25:596-604.